Jubilant Draximage INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$256Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
59clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Douglas Vannostrand | Washington, DC | Nuclear Medicine | $146,403.59 |
| Sergio Schwartzman | New York, NY | Rheumatology | $26,500.00 |
| John Maris | Philadelphia, PA | Pediatric Hematology-Oncology | $21,418.00 |
| Guido Davidzon | Palo Alto, CA | Nuclear Radiology | $10,300.00 |
| Mouaz Al-Mallah | Detroit, MI | Cardiovascular Disease | $8,170.10 |
| Leonard Freeman | Bronx, NY | Nuclear Medicine | $6,510.74 |
| Seza Gulec | Aventura, FL | Surgical Oncology | $6,000.00 |
| Rajen Mody | Ann Arbor, MI | Pediatric Hematology-Oncology | $5,716.67 |
| Bennett Greenspan | Augusta, GA | Diagnostic Radiology | $3,236.15 |
| Jerry Froelich | Minneapolis, MN | Diagnostic Radiology | $2,400.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.